Hit identification

Don’t miss your chance to register for the free webinar, Introduction into Fragment Based Drug Discovery, hosted by DDW and supported by WuXi AppTec. The event will take place on Thursday, October 13 at 3PM BST, 4PM CET, 10AM EST, 7AM PDT. Attendees will learn: How FBDD can help identify novel and potent lead compounds.   The benefits […]

Fragment-based drug discovery (FBDD) is one strategy used to identify novel and potent lead compounds.   Don’t miss out on this free webinar, Introduction into Fragment Based Drug Discovery, hosted by DDW and supported by WuXi AppTec. Fragments are small molecules with a low molecular weight (less than 250 g/mol). The FBDD technology is based on identifying these small […]

Fragment-based drug discovery (FBDD) is one strategy of hit identification (hit ID) in the drug discovery process. Watch the webinar, Introduction into Fragment Based Drug Discovery, hosted by DDW and supported by WuXi AppTec. Key Learning Objectives:   How FBDD can help identify novel and potent lead compounds.   Understand the benefits of FBDD technology compared to high throughput screening […]

Watch the free webinar, Introduction into Fragment Based Drug Discovery, hosted by DDW and supported by WuXi AppTec. Fragment-based drug discovery (FBDD) is a method used for finding hit compounds as one strategy of hit identification (hit ID) in the drug discovery process. Fragments are small molecules with a low molecular weight (less than 250 g/mol). […]

Fragment-based drug discovery (FBDD) is a method used for finding hit compounds as one strategy of hit identification (hit ID) in the drug discovery process.   Introduction into Fragment Based Drug Discovery, hosted by DDW and supported by WuXi AppTec, is now available to watch online.  Fragments are small molecules with a low molecular weight (less […]

Fragment-based drug discovery (FBDD) is a method used for finding hit compounds as one strategy of hit identification (hit ID) in the drug discovery process.   Watch this free event, Introduction into Fragment Based Drug Discovery, hosted by DDW and supported by WuXi AppTec.  Fragments are small molecules with a low molecular weight (less than 250 g/mol). […]

The latest free-to-listen DDW podcast episode is titled “Using biotechnology to maximise drug discovery output”. It covers two articles written for Volume 22, Issue 2 – Spring 2021 of the Drug Discovery World Magazine and has been narrated by DDW’s Megan Thomas.  These articles are titled: “The important integration of medicinal chemistry in Hit-to-Lead discovery” and “With so many technologies for genetically […]

APEIRON Biologics, a biotech company developing breakthrough therapies to treat cancer and respiratory conditions, has selected Domainex to provide integrated lead optimisation services in order to advance the development of inhibitors for the E3 ubiquitin ligase Cbl-b through small molecule drug discovery. Under the terms of the agreement, Domainex, an integrated drug discovery research service […]